50 results about "Low density lipoprotein cholesterol level" patented technology

Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w / w) of exenatide, about 2% (w / w) of sucrose, and about 93% (w / w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microshperes encapsulating the exenatide.

The invention relates to a method for treating Syndrome X, or inhibiting the onset of symptoms of Syndrome X in a patient, and includes administering a therapeutically effective amount of a salt of at least one alkylated and cross-linked polymer, or a copolymer thereof, the polymer salt formed as a product of the reaction of one or more polymers, or salts and copolymers thereof, having a repeat unit that is essentially: where n is a positive integer and each R, independently, is H or a C1-C8 alkyl group; at least one aliphatic alkylating agent; and a cross-linking agent. Long term administration of the cross-linked polyamine salts of the invention increases HDL levels and decreases LDL levels in patients. The invention also provides for administration of the polymer salt colesevelam, in combination with an HMG-CoA reductase inhibitor; the combined administration is effective in further lowering serum total-cholesterol and LDL-cholesterol levels beyond that achieved by either agent alone.

A food product suitable for reducing low density lipoprotein cholesterol levels comprising an amount of soy protein of at least 5 grams per average serving and at least 5 mg / kg statins is described. Preferably the food product comprises a fermented soy ingredient.

A method for measuring LDL cholesterol in a sample using a test piece is provided which involves a step of measuring the total cholesterol in the sample; a step of measuring the non-LDL cholesterol in the sample; and a step of subtracting the non-LDL cholesterol value from the total-cholesterol value to obtain the LDL cholesterol level.

The invention discloses the drug application of epimedin C for treating diabetic liver injury, and belongs to the technical field of biomedicine. The present invention discloses for the first time that epimedin C can increase the level of high-density lipoprotein cholesterol in the liver of diabetic model animals, reduce the level of low-density lipoprotein cholesterol in the liver, alleviate the problem of lipid metabolism disorder, reduce liver index, and enhance superoxide dismutase in the liver , Glutathione peroxidase activity, reduce malondialdehyde content, improve liver oxidative stress state, maintain normal shape and structure of liver cells and tissues, reduce liver alanine aminotransferase and aspartate aminotransferase activity levels, and promote liver function repair, Therefore, it can be used to prepare medicines for treating diabetic liver damage. Epimedin C prepares a medicine for treating diabetic liver damage and uses it in the form of pharmaceutical preparations, including buccal tablets, coated tablets and hard capsules. The invention provides a basis for the treatment of diabetic liver damage, and also provides ideas for the deep development and utilization of epimedium resources.

The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.

Application of the pigeon pea ketonic acid A and a pharmaceutically acceptable derivative thereof in preparation of a medicine for a diabetes-accompanying disease or hyperlipidemia as well as a functional health product. The diabetes-accompanying disease is hyperlipidemia, liver damage, kidney damage, or pancreas damage accompanying diabetes.

The present invention provides methods and compositions for treating arteriosclerotic vascular diseases by cyclohexenone compounds. In some embodiments, the compound in the methods inhibits PDGF-stimulated smooth muscle cell proliferation or migration. In some embodiments, the atherosclerosis is associated with coronary artery disease, aneurysm, arteriosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plaque inflammation, vascular plaque rupture, Kawasaki disease, calcification or inflammation. In some embodiments, the compound lowers low-density lipoprotein (LDL) cholesterol in the subject. In some embodiments, the compound maintains a normal low-density lipoprotein (LDL) cholesterol level in the subject.